ACIP Recommendation for Novavax COVID-19 vaccine, adjuvanted for persons aged 18 years and older

Approval of ACP’s Immunization Committee (IC) to support the ACIP recommendation for use of Novavax COVID-19 vaccine for persons aged 18 years and older.

Approved July 25, 2022 by the Executive Committee of the Board of Regents on behalf of the Board of Regents

Background:

On Tuesday, July 19, 2022, the ACIP met and voted to recommend the Novavax COVID-19 vaccine, adjuvanted (two-dose) as a primary COVID-19 vaccine series for persons 18 years of age and older under the Emergency Use Authorization (EUA) issued by Food and Drug Administration (FDA).

ACP’s Immunization Committee (IC) conducted a vote by email on July 21-25, 2022. All IC members, including Vidya Sundareshan, MD, FACP (Chair); Michael Bronze, MD, MACP; Jason Goldman, MD, FACP; Saba Hasan, MD, FACP; Noel N. Deep, MD, FACP; Susan Lee, MD, FACP; and Kristin Mitchell, MD, FACP, voted unanimously to support the ACIP recommendations for the Novavax COVID-19 vaccine primary series.

The IC recommends that the ECBOR support the ACIP recommendations for use of the Novavax COVID-19 vaccine, adjuvanted (two-dose, primary series) for persons aged 18 years and older under the FDA's EUA.

Key background resources: